secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0000950170-24-085860
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q2 2024 GAAP EPS $0.55; proprietary sales up 16% YoY; reiterates guidance
--------------------------------------------------------------------------------

- Total revenues $399.1M, GAAP net income from continuing ops $94.7M; non-GAAP net income $123.4M.
- Proprietary net sales $269.3M (+16% YoY); LYBALVI $71.4M (+52%), VIVITROL $111.9M (+10%).
- Cash & investments $962.5M; repurchased 3.5M shares for $84.7M in Q2; $315.3M remaining.
- Positive phase 1b ALKS 2680 data in narcolepsy; initiated Vibrance-1 phase 2 for NT1.
- Reiterated 2024 financial expectations; sold Athlone facility to Novo Nordisk for ~$91M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/0000950170-24-085860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/alks-20240724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer